Share on LinkedInShare on LinkedIn

ARTICLE · 21 APRIL 2015

First Secondary Market Class Action To Reach SCC Denied Leave

Blake, Cassels & Graydon LLP
Blake, Cassels & Graydon LLP
Contributor
Blake, Cassels & Graydon LLP

Blake, Cassels & Graydon LLP

As one of Canada’s top business law firms, Blake, Cassels & Graydon LLP (Blakes) provides...

View firm profile
Explore more from Blake, Cassels & Graydon LLP

In a decision released on April 17, 2015, the Supreme Court of Canada (SCC) overturned the Québec Court of Appeal’s judgment in Theratechnologies Inc. v. 121851 Canada Inc. (See our July 2013 Blakes Bulletin: Statutory Secondary Market Misrepresentation Claims: Quebec Court of Appeal’s First Decision for more information.)

CanadaCorporate/Commercial Law

In a decision released on April 17, 2015, the Supreme Court of Canada (SCC) overturned the Québec Court of Appeal's judgment in Theratechnologies Inc. v. 121851 Canada Inc. (See our July 2013 Blakes Bulletin: Statutory Secondary Market Misrepresentation Claims: Quebec Court of Appeal's First Decision for more information.)

For the first time, the SCC considered the standard for granting a plaintiff leave to proceed with a statutory secondary market securities class action. The SCC held that courts must undertake a reasoned consideration of the evidence adduced on the leave motion to ensure that the proposed class action has some merit.

BACKGROUND

The plaintiff claimed that Theratechnologies Inc. (Thera) failed to comply with continuous disclosure obligations pursuant to the Quebec Securities Act (QSA) in that Thera did not disclose a request for information from the U.S. Food and Drug Administration (FDA) issued in the context of the drug approval process. The

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from